Researchers proved its potential in differentiating between the demyelinating disorders of the CNS since evidence shows that 78% of patients with MS are positive, compared to only 8% of patients with NMOSD (either seropositive or seronegative for AQP4). Here, AQP4 is linked to myeloid sarcoma.